INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) (NCT07429266)
A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy. The study will be conducted in three sequential parts (Part 1a blinded treatment, Part 1b open-label treatment, \& Part 2 long-term extension). Participants may receive treatment for up to 156 weeks.
Who can join: Review the eligibility criteria below.
Location: Regis Clinical Research LLC. — Miami, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Regis Clinical Research LLC. — Miami, Florida
- Florida Clinical Trials Group — Plantation, Florida
- Florida Clinical Trials Group — Tamarac, Florida
- The Center for Cancer & Blood Disorders — Bethesda, Maryland
- The Cancer and Hematology Centers — Grand Rapids, Michigan
- Montefiore Medical Center — The Bronx, New York
- Gabrail Cancer Center Research — Canton, Ohio
- Perth Blood Institute — West Perth, Western Australia
📞 Contact the Study Coordinator
Phone: (888) 724-3274
Email: clinicaltrials@deciphera.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Polycythemia Vera
- A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera — Mobile, Alabama
- Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera — Covington, Louisiana
- KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera — Birmingham, Alabama
- Study to Assess SLN124 in Patients With Polycythemia Vera — Hammond, Louisiana
- A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV — Jacksonville, Florida
- A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes — Rochester, Minnesota
Explore by condition: All Polycythemia Vera clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.